--- title: "FDA abortion pill review to continue into next year" publication: "MediaBias News" url: "https://mediabias.news/health/fda-abortion-pill-review-to-continue-into-next-year" api: "https://mediabias.news/api/v1/stories/fda-abortion-pill-review-to-continue-into-next-year" markdown: "https://mediabias.news/health/fda-abortion-pill-review-to-continue-into-next-year.md" audio: "https://mediabias.news/api/audio/fda-abortion-pill-review-to-continue-into-next-year" category: "Health" area: "United States" published: "2026-10-08T04:45:29.917Z" source_reported: "2026-10-08T03:57:27.000Z" updated: "2026-10-08T04:45:29.917Z" trust_score: 42 critic_score: 59 hype_score: 41 assessment_type: "coverage-and-source-reporting-analysis" fact_check_status: "not-performed" coverage_measured: "2026-10-08T06:45:12.394921+00:00" --- # FDA abortion pill review to continue into next year *Agency provides court-ordered update on safety study of mifepristone* **Scores for the source reporting** (0-100, assessing the original journalism this article was written from, not this write-up): - Trust 42 of 100, higher is better. Central claim attributed to FDA filing; one full report and 23 digests; no named sources. - Craft 59 of 100, higher is better. One full report and 23 digests; quotes from one named individual; some outlets provide context. - Hype 41 of 100, lower is better. Headlines promise a definitive completion date, but the article details a review process extending into next year. Scored by MediaBias News; method at https://mediabias.news/methodology. **The short version** - The Food and Drug Administration's safety review of the abortion pill mifepristone will continue into next year. - The FDA provided a court-ordered update on its progress in a legal filing on Wednesday. - The agency expects to finish a safety study by mid-December and issue a report on findings no later than March 2027. - Abortion opponents have criticised the timeline, while the FDA was directed to provide the update by a federal appeals court. The Food and Drug Administration (FDA) has stated that its safety review of mifepristone, the nation's primary abortion pill, will continue into next year. This timeline was communicated in a legal filing submitted late Wednesday, fulfilling a court order. The agency anticipates completing a safety study of the drug by mid-December of this year. A report detailing the findings is expected to be released no later than March 2027, after which the FDA will determine whether to implement any new restrictions or modifications to the drug's use. The FDA was directed to provide this update by a federal appeals court in New Orleans. This directive stems from a legal case brought by the state of Louisiana, which alleges that the mail delivery of mifepristone conflicts with the state's abortion ban. Mifepristone was first approved by the FDA in 2000 and has had its restrictions eased over time, including the removal of a requirement for in-person dispensing. ## Disagreement on timeline for report While ABC News, The Independent, and The Independent (US) report that a report on the findings is expected no later than March 2027, The Hill states the FDA revealed it won't publish its mifepristone safety review until March 2027. NBC News and NBC Dallas-Fort Worth report the FDA says it will complete the safety review in March, with NBC Dallas-Fort Worth specifying the review will be completed in March. ## What the coverage left out None of the left-rated digests mention the specific criticism from Gavin Oxley of Americans United for Life that the administration is 'clearly uninterested in mitigating the ongoing harms caused by the abortion pill'. The right-rated digest does not mention the FDA's expected completion date for the safety study (mid-December this year) or the expected date for the report on findings (no later than March 2027). ## Who covered it Shares of the 25 covering outlets with a published leaning rating: - Left: 64% (16) - Centre: 32% (8) - Right: 4% (1) 3 of 28 covering outlets carried no usable leaning rating and were excluded from those percentages. Coverage measured 2026-10-08T06:45:12.394921+00:00. **Coverage watch:** developing. Checked 3 times; 0 checks found a material change. Most recently checked 2026-10-08T07:00:32.353Z. ## How the sides framed it ### Left - Fifteen left-rated reports noted that the FDA's safety review of the abortion pill mifepristone will continue into next year. These reports stated that the FDA provided a court-ordered update on its progress in a legal filing late Wednesday. They also included that the agency expects to complete a safety study by mid-December this year and that a report on the findings is expected no later than March 2027. Several of these reports mentioned that the FDA was directed to provide the update by a federal appeals court in New Orleans, overseeing a case brought by the state of Louisiana. ABC News, the only full report in this category, also included criticism from Gavin Oxley of Americans United for Life, who called the move a lack of 'true leadership' and stated the administration was 'on the wrong side of women's health'. ### Centre - Six centre-rated reports highlighted that the FDA's safety review of the abortion pill mifepristone will continue into next year. These reports noted the FDA provided a court-ordered update on its progress in a legal filing late Wednesday. They also mentioned the agency expects to complete a safety study by mid-December this year and that a report on the findings is expected no later than March 2027. The Hill, a centre-rated outlet, reported that the FDA revealed it won't publish its mifepristone safety review until March 2027, sparking criticism from both sides. ### Right - The single right-rated report, a statement from SBA Pro-Life America, focused on the upcoming court-ordered deadline for the FDA's mifepristone study update. It quoted SBA Pro-Life America President Marjorie Dannenfelser referencing Dr. Heidi Overton's commitment to conduct an abortion drug study. This report did not mention the timeline for the completion of the safety review or the expected date for the report on findings. **Provisional coverage gap:** right. The watch is not closed, so this is not yet a settled blindspot finding. ## Factuality profile of the covering outlets These are published factuality ratings of the outlets, not a verdict on whether this story or its claims are true. - mixed: 2 - high: 9 - unknown: 3 - veryHigh: 14 ## Verification scope This page compares coverage and scores the source reporting. It is not a ClaimReview verdict on whether the underlying event or claim is true. ## Original reporting this was written from - [My Mother Lode](https://mymotherlode.com/news/national/11203240/fda-says-its-safety-review-of-abortion-pill-will-continue-into-next-year.html) — FDA says its safety review of abortion pill will continue into next year - [Rocky Mountain Outlook](https://rmoutlook.com/lifestyle/fda-says-its-safety-review-of-abortion-pill-will-continue-into-next-year-12870830) — FDA says its safety review of abortion pill will continue into next year - [Airdrie City View](https://airdriecityview.com/lifestyle/fda-says-its-safety-review-of-abortion-pill-will-continue-into-next-year-12870830) — FDA says its safety review of abortion pill will continue into next year - [Bowen Island Undercurrent](https://bowenislandundercurrent.com/the-mix/fda-says-its-safety-review-of-abortion-pill-will-continue-into-next-year-12870854) — FDA says its safety review of abortion pill will continue into next year - [Loonie Politics](https://looniepolitics.com/fda-says-its-safety-review-of-abortion-pill-will-continue-into-next-year) — FDA says its safety review of abortion pill will continue into next year - [Rutland Herald](https://rutlandherald.com/ap/washington/fda-says-its-safety-review-of-abortion-pill-will-continue-into-next-year/article_9719201c-3afd-502c-a1ab-0f39fb0afed9.html) — FDA says its safety review of abortion pill will continue into next year - [The Toronto Star](https://thestar.com/news/world/fda-says-its-review-of-abortion-pill-will-continue-into-next-year/article_c65e424b-aa73-5d86-aa75-213b8e2862c1.html) — FDA says its safety review of abortion pill will continue into next year - [thealbertan.com](https://thealbertan.com/lifestyle/fda-says-its-review-of-abortion-pill-will-continue-into-next-year-12870830) — FDA says its review of abortion pill will continue into next year - [El Paso Inc.](https://elpasoinc.com/news/ap_wire/fda-says-its-review-of-abortion-pill-will-continue-into-next-year/article_8dafd508-4552-57dd-9599-e5f40eea5cfc.html) — FDA says its review of abortion pill will continue into next year - [Bozeman Daily Chronicle](https://bozemandailychronicle.com/wire/national/fda-says-its-review-of-abortion-pill-will-continue-into-next-year/article_d2a54988-2909-5ceb-8bab-91beac41da79.html) — FDA says its review of abortion pill will continue into next year - [Washington Top News](https://wtop.com/national/2026/10/fda-says-its-review-of-abortion-pill-will-continue-into-next-year) — FDA says its review of abortion pill will continue into next year – WTOP News - [The Seattle Times](https://seattletimes.com/seattle-news/health/fda-says-its-review-of-abortion-pill-will-continue-into-next-year) — FDA says its safety review of abortion pill will continue into next year - [WBAL](https://wbal.com/fda-says-its-review-of-abortion-pill-will-continue-into-next-year) — FDA says its safety review of abortion pill will continue into next ye - [The Independent](https://independent.co.uk/news/fda-donald-trump-washington-white-house-congress-b3063182.html) — FDA says its review of abortion pill will continue into next year - [The Independent (US)](https://the-independent.com/news/fda-donald-trump-washington-white-house-congress-b3063182.html) — FDA says its review of abortion pill will continue into next year - [abc News](https://abcnews.com/Health/wireStory/fda-review-abortion-pill-continue-year-137085063) — FDA says its review of abortion pill will continue into next year - [WKMG](https://clickorlando.com/news/politics/2026/10/08/fda-says-its-review-of-abortion-pill-will-continue-into-next-year) — FDA says its review of abortion pill will continue into next year - [Bangor Daily News](https://bangordailynews.com/2026/10/07/nation/fda-says-its-safety-review-of-abortion-pill-will-continue-into-next-year) — FDA says its safety review of abortion pill will continue into next year - [KXL](https://kxl.com/fda-says-its-review-of-abortion-pill-will-continue-into-next-year) — FDA says its safety review of abortion pill will continue into next year - [The Hill](https://thehill.com/policy/healthcare/6135515-fda-mifepristone-abortion-pill-review-delay) — FDA: Mifepristone review won’t be done until March - [NBC News](https://nbcnews.com/health/health-news/fda-says-will-complete-safety-review-abortion-pill-march-rcna602161) — FDA says it will complete safety review of abortion pill in March - [The Hamilton Spectator](https://thespec.com/life/fda-says-its-review-of-abortion-pill-will-continue-into-next-year/article_75a49b5e-5765-5495-ab05-f21d0db62518.html) — FDA says its safety review of abortion pill will continue into next year - [The Record](https://therecord.com/life/fda-says-its-review-of-abortion-pill-will-continue-into-next-year/article_05c13a64-e178-513e-bc59-b070d24281ce.html) — FDA says its safety review of abortion pill will continue into next year - [St Catharines Standard](https://stcatharinesstandard.ca/life/fda-says-its-review-of-abortion-pill-will-continue-into-next-year/article_f8ff36d2-4a2c-598e-8193-4df54aaf6446.html) — FDA says its safety review of abortion pill will continue into next year - [Winnipeg Free Press](https://winnipegfreepress.com/arts-and-life/life/2026/10/07/fda-says-its-review-of-abortion-pill-will-continue-into-next-year) — FDA says its safety review of abortion pill will continue into next year - [NBC Dallas-Fort Worth](https://nbcdfw.com/news/health/fda-says-it-will-complete-safety-review-of-abortion-pill-in-march/4088366) — FDA says it will complete safety review of abortion pill in March - [Politico](https://politico.com/newsletters/politico-pulse/2026/10/07/fda-faces-court-test-on-abortion-pill-review-01108998) — FDA faces court test on abortion pill review - [SBA Pro-Life America](https://sbaprolife.org/newsroom/press-releases/statement-ahead-fdas-oct-7-deadline-mifepristone-study-update) — Statement Ahead of FDA's Oct. 7 Deadline for Mifepristone Study Update ## Questions **When will the FDA complete its safety review of the abortion pill?** The Food and Drug Administration expects to complete a safety study of the abortion pill mifepristone by mid-December this year. A report on the findings is anticipated no later than March 2027, after which the agency will decide on potential new restrictions or changes to the drug's use. **Why did the FDA provide an update on the abortion pill review?** The FDA provided the update in a legal filing late Wednesday because it was ordered to do so by a federal appeals court in New Orleans. This directive is part of a lawsuit brought by the state of Louisiana, which is challenging the mail delivery of mifepristone. **What is the timeline for the FDA's report on the mifepristone safety review?** The FDA expects to complete its safety study of mifepristone by mid-December this year. A report detailing the findings from this study is expected to be published no later than March 2027. --- MediaBias News — https://mediabias.news. Reproduced from https://mediabias.news/health/fda-abortion-pill-review-to-continue-into-next-year. Please cite as: MediaBias News, "FDA abortion pill review to continue into next year", https://mediabias.news/health/fda-abortion-pill-review-to-continue-into-next-year